ACOG (Alpha Cognition) Additional Paid-In Capital: $31.49 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACOG Alpha Cognition Inc ACOG
35 GF Score
Price $8.93
! 5 Warning Signs
View Full Analysis

What is Alpha Cognition Additional Paid-In Capital?

Alpha Cognition ACOG -0.50% 35 Additional Paid-In Capital is $31.49 Mil as of Jun. 2026. GuruFocus rates ACOG with a GF Score™ of 35/100. The stock has 5 warning signs investors should review.


Alpha Cognition's quarterly additional paid-in capital increased from Dec. 2025 ($25.85 Mil) to Mar. 2026 ($27.19 Mil) and increased from Mar. 2026 ($27.19 Mil) to Jun. 2026 ($31.49 Mil).

Alpha Cognition's annual additional paid-in capital increased from Dec. 2023 ($ Mil) to Dec. 2024 ($16.51 Mil) and increased from Dec. 2024 ($16.51 Mil) to Dec. 2025 ($25.85 Mil).

Alpha Cognition Additional Paid-In Capital Related Terms

Alpha Cognition Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Alpha Cognition's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Cognition Additional Paid-In Capital Chart

Alpha Cognition Annual Data
Trend Jul18 Jul19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial - - - 16.51 25.85

Alpha Cognition Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.63 22.29 25.85 27.19 31.49
ACOG
35GF Score
Alpha Cognition Inc ACOG
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Cognition Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $31.49 Mil mean?
Alpha Cognition (ACOG) has a Additional Paid-In Capital of $31.49 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Alpha Cognition and its competitors.
Is Alpha Cognition's Additional Paid-In Capital too high?
Alpha Cognition's current Additional Paid-In Capital is $31.49 Mil. Overall, Alpha Cognition has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's Additional Paid-In Capital compare to NKTX and ARMP?
Alpha Cognition's Additional Paid-In Capital of $31.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Alpha Cognition and its competitors. Alpha Cognition's current Additional Paid-In Capital is $31.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (ACOG) has a current Additional Paid-In Capital of $31.49 Mil. The current Additional Paid-In Capital is $31.49 Mil. Alpha Cognition's overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current Additional Paid-In Capital is $31.49 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Cognition Business Description

Other Exchanges 7N70:Germany
Address 1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
35GF Score

Get the complete analysis for ACOG

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.93
Price